You are here
This report was prepared in accordance with the requirements of the National Health Reform Act 2011 and section 46 of the Public Governance, Performance and Accountability Act 2013. The report includes IHPA's audited Financial Statements, as required by section 42 of the Public Governance, Performance and Accountability Act.
The goal of the Consultation and review of the AR-DRG and ICD-10-AM/ACHI/ACS Classification Systems report was to review the end-to-end development processes, implementation arrangements and user needs in developing and implementing updates to the following classifications, now and into the future:
This document guides costing practitioners on the steps to capturing end-to-end COVID-19 activity and expenses under the National Partnership Agreement (NPA). It identifies the principles to be applied, the scope of activity and costs to be funded, cost allocation methods and NPA specific cost centres for cost allocation. This document also introduces two new non-patient products and provides information on how to create and map intermediate products.
National Hospital Cost Data Collection, Data Request Specifications, Round 24 (Financial Year 2019-20)30 July 2020
The National Hospital Cost Data Collection (NHCDC) Data Request Specifications (DRS) contain detailed guidance regarding the submission of Round 24 NHCDC data.
The IHPA Data Compliance Policy describes the process and criteria by which IHPA will publicly report on compliance by jurisdictions with the data requirements and data submission dates specified in the current Three Year Data Plan 2020–21 to 2022–23.
As prescribed in Section 225 of the National Health Reform Act 2011, the objectives of the IHPA Work Program are to:
- set out IHPA’s work program for the coming year; and
- invite interested persons (including states and territories) to make submissions to the Pricing Authority about the Work Program up to 30 days after publication.
An extract of Section 225 of the Act is attached at Appendix 1.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions. This data plan sets out IHPA's eighth rolling Three Year Data Plan, covering the period 2020–21 to 2022–23. The Three Year Data Plan specifies the data requirements and timelines that IHPA will use to collect data over the next three years.
Each year, IHPA publishes the General List of In-Scope Public Hospital Services (the General List) as part of the National Efficient Price Determination.
The General List defines public hospital services eligible for Commonwealth funding, except where funding is otherwise agreed between the Commonwealth and a state or territory.
IHPA has a role to investigate and make recommendations concerning cross-border disputes between states and territories, and to make assessments of cost-shifting disputes. This Framework outlines the processes to investigate these disputes following a request by a health minister to ensure the timely, equitable and transparent management of these disputes.
A jurisdiction may request IHPA to consider any legitimate and unavoidable costs in the delivery of public hospital services. The purpose of this Framework is to assist jurisdictions in making submissions to IHPA on this issue, to layout the process which IHPA will follow in assessing submissions, and the process to determine adjustments to the NEP.
IHPA recognises the need for the pricing of public hospital services to respond in a timely manner to the introduction of new health technologies and innovations in models of care.
The purpose of the Management of Confidential Jurisdictional Information Protocol is to advise jurisdictions of the processes and controls adopted by IHPA in managing confidential jurisdictional information as part of its rolling Three Year Data Plan.
IHPA is responsible for relevant data collections to enable activity based funding. IHPA’s Data Access and Release Policy outlines the principles and processes adopted by IHPA in the discretionary access and release of data collected under the National Health Reform Act 2011. The Policy provides guidance as to how IHPA will determine whether to release data.
Following the completion of the 2016 Inter-Rater Reliability (IRR) study to test the consistency of clinician application of the mental health phase of care, the poor to fair reliability outcome led to the commencement of the refinement project.